Incidence and outcomes of patients with late recurrence of Wilms' tumor

Marcio Malogolowkin, F. Spreafico, J. S. Dome, H. van Tinteren, K. Pritchard-Jones, M. M. van den Heuvel-Eibrink, C. Bergeron, J. de Kraker, N. Graf

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Most relapses from Wilms' tumor occur within 2 years from diagnosis. This study aims to describe the incidence and outcome of patients who experienced a late recurrence (LR) more than 5 years after diagnosis across several clinical trials, and to develop evidence-based recommendations for follow-up surveillance. Methods: Available records on children with Wilms' tumor enrolled onto 10 national or international cooperative clinical trials were reviewed to identify patients who experienced a LR. Results: Seventy of 13,330 (0.5%) patients with Wilms' tumor experienced a LR. No gender bias was observed. Median time elapsing between initial Wilms' tumor diagnosis and first recurrence was 13.2 years (range: 5.1-17.3 years). Initial tumor stage was: stage I (15); stage II (19); stage III (14); stage IV (8); bilateral disease stage V (14). The most frequent sites of relapse were-abdomen: 21, lungs: 20, and contralateral kidney: 15. Thirty-five children died of disease progression. Recurrence in the contralateral kidney was associated with a better outcome (13/15 patients alive), while initial tumor stage did not seem to influence the post-recurrence outcome. Therapies administered at recurrence varied between centers, preventing any conclusion about the best salvage treatment. Conclusions: LR of Wilms' tumor is rare and associated with similar outcome to those experiencing earlier recurrence. The low rate of LR does not justify prolonged monitoring. Further study of the biology of these tumors may give us some insights in regards to mechanisms on tumor cell dormancy or cancer stem cell maintenance. Pediatr Blood Cancer 2013;60:1612-1615.

Original languageEnglish (US)
Pages (from-to)1612-1615
Number of pages4
JournalPediatric Blood and Cancer
Volume60
Issue number10
DOIs
StatePublished - Oct 1 2013
Externally publishedYes

Fingerprint

Wilms Tumor
Recurrence
Incidence
Neoplasms
Clinical Trials
Kidney
Sexism
Salvage Therapy
Neoplastic Stem Cells
Abdomen
Disease Progression
Maintenance

Keywords

  • Incidence
  • International experience
  • Late relapse
  • Outcomes
  • Wilms' tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Malogolowkin, M., Spreafico, F., Dome, J. S., van Tinteren, H., Pritchard-Jones, K., van den Heuvel-Eibrink, M. M., ... Graf, N. (2013). Incidence and outcomes of patients with late recurrence of Wilms' tumor. Pediatric Blood and Cancer, 60(10), 1612-1615. https://doi.org/10.1002/pbc.24604

Incidence and outcomes of patients with late recurrence of Wilms' tumor. / Malogolowkin, Marcio; Spreafico, F.; Dome, J. S.; van Tinteren, H.; Pritchard-Jones, K.; van den Heuvel-Eibrink, M. M.; Bergeron, C.; de Kraker, J.; Graf, N.

In: Pediatric Blood and Cancer, Vol. 60, No. 10, 01.10.2013, p. 1612-1615.

Research output: Contribution to journalArticle

Malogolowkin, M, Spreafico, F, Dome, JS, van Tinteren, H, Pritchard-Jones, K, van den Heuvel-Eibrink, MM, Bergeron, C, de Kraker, J & Graf, N 2013, 'Incidence and outcomes of patients with late recurrence of Wilms' tumor', Pediatric Blood and Cancer, vol. 60, no. 10, pp. 1612-1615. https://doi.org/10.1002/pbc.24604
Malogolowkin M, Spreafico F, Dome JS, van Tinteren H, Pritchard-Jones K, van den Heuvel-Eibrink MM et al. Incidence and outcomes of patients with late recurrence of Wilms' tumor. Pediatric Blood and Cancer. 2013 Oct 1;60(10):1612-1615. https://doi.org/10.1002/pbc.24604
Malogolowkin, Marcio ; Spreafico, F. ; Dome, J. S. ; van Tinteren, H. ; Pritchard-Jones, K. ; van den Heuvel-Eibrink, M. M. ; Bergeron, C. ; de Kraker, J. ; Graf, N. / Incidence and outcomes of patients with late recurrence of Wilms' tumor. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 10. pp. 1612-1615.
@article{978a16fc12a145378e351bcfb600add9,
title = "Incidence and outcomes of patients with late recurrence of Wilms' tumor",
abstract = "Background: Most relapses from Wilms' tumor occur within 2 years from diagnosis. This study aims to describe the incidence and outcome of patients who experienced a late recurrence (LR) more than 5 years after diagnosis across several clinical trials, and to develop evidence-based recommendations for follow-up surveillance. Methods: Available records on children with Wilms' tumor enrolled onto 10 national or international cooperative clinical trials were reviewed to identify patients who experienced a LR. Results: Seventy of 13,330 (0.5{\%}) patients with Wilms' tumor experienced a LR. No gender bias was observed. Median time elapsing between initial Wilms' tumor diagnosis and first recurrence was 13.2 years (range: 5.1-17.3 years). Initial tumor stage was: stage I (15); stage II (19); stage III (14); stage IV (8); bilateral disease stage V (14). The most frequent sites of relapse were-abdomen: 21, lungs: 20, and contralateral kidney: 15. Thirty-five children died of disease progression. Recurrence in the contralateral kidney was associated with a better outcome (13/15 patients alive), while initial tumor stage did not seem to influence the post-recurrence outcome. Therapies administered at recurrence varied between centers, preventing any conclusion about the best salvage treatment. Conclusions: LR of Wilms' tumor is rare and associated with similar outcome to those experiencing earlier recurrence. The low rate of LR does not justify prolonged monitoring. Further study of the biology of these tumors may give us some insights in regards to mechanisms on tumor cell dormancy or cancer stem cell maintenance. Pediatr Blood Cancer 2013;60:1612-1615.",
keywords = "Incidence, International experience, Late relapse, Outcomes, Wilms' tumor",
author = "Marcio Malogolowkin and F. Spreafico and Dome, {J. S.} and {van Tinteren}, H. and K. Pritchard-Jones and {van den Heuvel-Eibrink}, {M. M.} and C. Bergeron and {de Kraker}, J. and N. Graf",
year = "2013",
month = "10",
day = "1",
doi = "10.1002/pbc.24604",
language = "English (US)",
volume = "60",
pages = "1612--1615",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Incidence and outcomes of patients with late recurrence of Wilms' tumor

AU - Malogolowkin, Marcio

AU - Spreafico, F.

AU - Dome, J. S.

AU - van Tinteren, H.

AU - Pritchard-Jones, K.

AU - van den Heuvel-Eibrink, M. M.

AU - Bergeron, C.

AU - de Kraker, J.

AU - Graf, N.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: Most relapses from Wilms' tumor occur within 2 years from diagnosis. This study aims to describe the incidence and outcome of patients who experienced a late recurrence (LR) more than 5 years after diagnosis across several clinical trials, and to develop evidence-based recommendations for follow-up surveillance. Methods: Available records on children with Wilms' tumor enrolled onto 10 national or international cooperative clinical trials were reviewed to identify patients who experienced a LR. Results: Seventy of 13,330 (0.5%) patients with Wilms' tumor experienced a LR. No gender bias was observed. Median time elapsing between initial Wilms' tumor diagnosis and first recurrence was 13.2 years (range: 5.1-17.3 years). Initial tumor stage was: stage I (15); stage II (19); stage III (14); stage IV (8); bilateral disease stage V (14). The most frequent sites of relapse were-abdomen: 21, lungs: 20, and contralateral kidney: 15. Thirty-five children died of disease progression. Recurrence in the contralateral kidney was associated with a better outcome (13/15 patients alive), while initial tumor stage did not seem to influence the post-recurrence outcome. Therapies administered at recurrence varied between centers, preventing any conclusion about the best salvage treatment. Conclusions: LR of Wilms' tumor is rare and associated with similar outcome to those experiencing earlier recurrence. The low rate of LR does not justify prolonged monitoring. Further study of the biology of these tumors may give us some insights in regards to mechanisms on tumor cell dormancy or cancer stem cell maintenance. Pediatr Blood Cancer 2013;60:1612-1615.

AB - Background: Most relapses from Wilms' tumor occur within 2 years from diagnosis. This study aims to describe the incidence and outcome of patients who experienced a late recurrence (LR) more than 5 years after diagnosis across several clinical trials, and to develop evidence-based recommendations for follow-up surveillance. Methods: Available records on children with Wilms' tumor enrolled onto 10 national or international cooperative clinical trials were reviewed to identify patients who experienced a LR. Results: Seventy of 13,330 (0.5%) patients with Wilms' tumor experienced a LR. No gender bias was observed. Median time elapsing between initial Wilms' tumor diagnosis and first recurrence was 13.2 years (range: 5.1-17.3 years). Initial tumor stage was: stage I (15); stage II (19); stage III (14); stage IV (8); bilateral disease stage V (14). The most frequent sites of relapse were-abdomen: 21, lungs: 20, and contralateral kidney: 15. Thirty-five children died of disease progression. Recurrence in the contralateral kidney was associated with a better outcome (13/15 patients alive), while initial tumor stage did not seem to influence the post-recurrence outcome. Therapies administered at recurrence varied between centers, preventing any conclusion about the best salvage treatment. Conclusions: LR of Wilms' tumor is rare and associated with similar outcome to those experiencing earlier recurrence. The low rate of LR does not justify prolonged monitoring. Further study of the biology of these tumors may give us some insights in regards to mechanisms on tumor cell dormancy or cancer stem cell maintenance. Pediatr Blood Cancer 2013;60:1612-1615.

KW - Incidence

KW - International experience

KW - Late relapse

KW - Outcomes

KW - Wilms' tumor

UR - http://www.scopus.com/inward/record.url?scp=84881501574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881501574&partnerID=8YFLogxK

U2 - 10.1002/pbc.24604

DO - 10.1002/pbc.24604

M3 - Article

C2 - 23737480

AN - SCOPUS:84881501574

VL - 60

SP - 1612

EP - 1615

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

ER -